FDA approves Qsymia to treat Obesity in adolescents

A recent research study has found that childhood obesity is more common now than 12 years ago – which is particularly troubling news, given that obesity increases the risk of insulin resistance and Type 2 diabetes.

However, the FDA has recently approved Qsymia for treatment of obesity for adolescents (ages 12-17), following a clinical trial for Qsymia, which found more than 44% of adolescent patients lost at least 15% of their body weight and more than 30% of patients lost at least 20% of their body weight.

To read more, CLICK HERE.


Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags